Anaplastic Astrocytoma

P2, N=19, Terminated, Exelixis | Completed --> Terminated; Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.

He received adjuvant concurrent radiation and temozolomide...We present a case of IDH-mutant astrocytoma with a somewhat atypical molecular presentation, including a previously uncharacterized IDH2 mutation, retained ATRX expression, and lack of MGMT promoter hypermethylation. Though it has not been biochemically or functionally validated, tumor methylation profiling is supportive of this previously uncharacterized IDH2 variant as tumorigenic.

P1/2, N=68, Not yet recruiting, Lantern Pharma Inc.

P1/2, N=53, Terminated, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2 | Completed --> Terminated; Unable to supply investigational agent, Zotiraciclib (TG02).

In contrast, COL4A2 and SOX10 appear to act as tumor suppressors in glioma pathophysiology. SOX10 may additionally be a valuable prognostic marker in female GBM patients.

Within the perivascular microenvironment, EV-mediated interactions between glioblastoma cells and astrocytes support the induction of stemness and the differentiation of GBM cells toward a pericyte-like phenotype, promoting perivascular niche formation and microvascular proliferation. The hydrogel-based co-culture model thus provides a simple and effective platform for dissecting tumor-stroma communication in the glioblastoma microenvironment.

P1/2, N=40, Not yet recruiting, National Institute of Neurological Disorders and Stroke (NINDS)

P=N/A, N=1, Completed, Daniela A. Bota | Active, not recruiting --> Completed

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

The molecular processes driving this resistance are complex and not yet fully understood. In this review, we briefly present the growth factor receptors (GFRs) and their signaling pathways in adult astrocytomas and discuss the known mechanisms of resistance to small-molecule tyrosine kinase inhibitors.

P1, N=56, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting

The left parietal tumor was diagnosed as a grade 4 astrocytoma with an IDH1 R132H mutation, while the left frontal tumor was classified as a grade 2 oligodendroglioma with an IDH1 R132S mutation. Given the distinct molecular profiles of both synchronous tumors, treatment consideration was given to each individual primary tumor.